



Biotech Daily

Tuesday July 10, 2018

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: FACTOR UP 12.5%; BENITEC DOWN 20%**
- * **CLARITY STARTS SARTATE FOR MENINGIOMA TRIAL**
- * **ITALY, CZECH REPUBLIC OKAY MEDICAL DEVELOPMENTS PENTHROX**
- * **ORTHOCELL APPOINTS CARRERA UK CELGRO DENTAL DISTRIBUTOR**
- * **US PATENT FOR REGENEUS PROGENZA STEM CELLS**
- * **OVENTUS TO RELEASE 37m SHARES, 1.2m OPTIONS FROM ASX ESCROW**
- * **PRIVATE PORTFOLIO MANAGERS TAKE 7% OF IMUGENE**
- * **ANTHONY BARTON, ASSOCIATES TAKE 6% OF PHYLOGICA**

MARKET REPORT

The Australian stock market fell 0.44 percent on Tuesday July 10, 2018 with the ASX200 down 27.9 points to 6,258.1 points.

Sixteen of the Biotech Daily Top 40 stocks were up, 14 fell, nine traded unchanged and one was untraded.

Factor Therapeutics was the best, up 0.6 cents or 12.5 percent to 5.4 cents with two million shares traded.

Uscom climbed 9.1 percent; Ellex improved 6.45 percent; Immutep was up 5.9 percent; Clinuvel, ITL, Neuren, Pro Medicus and Starpharma rose more than two percent; Airxpanders, Bionomics, Dimerix, Optiscan and Resmed were up one percent or more; with Nanosonics, Sirtex and Volpara up by less than one percent.

Yesterday's 110.3 percent best, Benitec, led the falls, easing six cents or 19.7 percent to 24.5 cents with 15.0 million shares traded.

Oncosil lost 8.5 percent; Prana shed 7.1 percent; Avita fell 5.9 percent; LBT was down 4.35 percent; Mesoblast, Opthea, Orthocell, Prescient and Universal Biosensors were down one percent or more; with Cochlear, Compumedics, CSL, Cyclopharm, Cynata and Medical Developments down by less than one percent.

CLARITY PHARMACEUTICALS

Clarity says that recruitment has begun in its six-patient, phase I/IIa trial of Sartate for the brain cancer meningioma at Sydney's Royal North Shore Hospital.

Clarity said that the peptide receptor radionuclide therapy trial using copper-64 Sartate for imaging and copper-67 Sartate for therapy was a single-centre, open-label, non-randomized diagnostic and therapy trial led by the hospital's Dr Geoffrey Schembri.

The company said that meningioma was the most frequent type of primary brain cancer that accounted for 36 percent of all intracranial tumors, with an incidence rate of 7.61 people per 100,000 and a male-to-female ratio of one-to-23.

Clarity said that the five-year overall survival rate was about 70 percent for benign meningiomas, 75 percent for atypical meningiomas and 55 percent for patients with anaplastic tumors.

Clarity executive chairman Dr Alan Taylor told Biotech Daily that first diagnostic results were expected within the week, with complete results expected by July 2019.

In a media release Dr Taylor said his company was "very excited to commence this trial at Royal North Shore Hospital".

"Not only are the results important to better treat this patient population, the data will also be used to progress Sartate into additional clinical trials for the treatment of children with neuroblastoma, an aggressive childhood cancer," Dr Taylor said.

"Clarity's ultimate goal is not only to improve survival rates of children and adults with cancer, but also minimize side effects and improve overall patient outcomes," he said.

Clarity is a public unlisted company.

MEDICAL DEVELOPMENTS INTERNATIONAL

Medical Developments says its Pentrox inhaled methoxyflurane analgesic has been approved for sale in Italy and the Czech Republic.

Medical Developments chief executive officer John Sharman said the company was "delighted to have received the approval for these countries and we expect sales to commence in these markets [this financial year]".

In April and May, the company said that Pentrox had been approved in more than 20 countries in Europe (BD: Apr 24, May 29, 2018).

Today, Medical Developments chief financial officer Mark Edwards told Biotech Daily the only European countries yet to approve Pentrox were Luxembourg, Lithuania and Spain.

Medical Developments fell three cents or 0.5 percent to \$5.76.

ORTHOCELL

Orthocell says it has appointed the Birmingham, England-based Carrera Medical as its exclusive UK distributor for its Celgro scaffold for dental bone and soft tissue repair.

Orthocell said that Carrera was part of the Birmingham-based GSH Dental Laboratory group of companies and the five-year agreement would provide "access to an attractive strategic market, with a rapid uptake of innovative medical devices and a growing healthcare expenditure per capita".

Orthocell managing director Paul Anderson said Carrera was a leader in the marketing and distribution of medical devices.

The company said that Carrera would undertake targeted promotion activities, initiate sales and expand the network of referring periodontists and oral and maxillofacial surgeons.

Orthocell fell half a cent or 1.6 percent to 30 cents.

REGENEUS

Regeneus says the US Patent Office has allowed a patent covering the composition and use of its Progenza fat-derived mesenchymal stem cells.

Regeneus said that the patent, titled 'Therapeutics using adipose cells and cell secretions' would provide commercial rights in the US until 2032.

The company said that corresponding patents had been granted in Australia and Japan and were being pursued for grant in other key territories including Europe.

Regeneus said Progenza was its "lead cell therapy technology ... [for] osteoarthritis and other musculoskeletal diseases [which had] the potential to be used for other inflammatory diseases that have limited treatment options" and it worked by secreting cytokines, growth factors and exosomes to reduce inflammation and pain and promote healing and repair.

The company said it had a collaboration and licence agreement with Tokyo's AGC Asahi Glass to manufacture Progenza for all clinical applications in Japan and it was in "advanced negotiations" with potential licencees for Japan (BD: Jan 22, Jun 21, 2017).

Regeneus said it had more than 70 patents or patent applications across multiple families. Regeneus was up two cents or 14.3 percent to 16 cents with 1.1 million shares traded.

OVENTUS MEDICAL

Oventus says that 37,009,158 shares and 1,204,392 options will be released from ASX escrow on July 24, 2018.

The company said that following the quotation of the 37,009,158 shares, there would be 105,939,212 shares available for trading on the ASX and no stock remaining in escrow.

Oventus said the 1,204,392 options were exercisable at 57.8 cents by February 23, 2021. Oventus was unchanged at 30 cents.

IMUGENE

The Sydney-based Private Portfolio Managers says it has become a substantial shareholder in Imugene with 224,551,412 shares or 7.12 percent.

Private Portfolio Managers said it bought shares between March 13 and July 9, 2018 when it acquired 94,006,582 shares for \$2,538,178 or 27 cents share.

In June, Imugene said it had raised \$12 million at 2.7 cents a share and last week said it had raised a further \$8.1 million in a share plan (BD: Jun 7, Jul 6, 2018).

Imugene was unchanged at 2.7 cents with 6.5 million shares traded.

PHYLOGICA

Anthony Barton says that with associates he has increased his substantial holding in Phylogica from 107,000,000 shares (5.01%) to 129,450,000 shares (6.1%).

The Perth-based former Phylogica director Mr Barton said he bought 22,450,000 shares on-market on July 9, 2018, but yet again, failed to disclose the cost as required under the Corporations Act 2001 (BD: Nov 17, 2016; Oct 25, 2017).

Mr Barton said the associates were Harvey Springs Estate, AP and CH Barton Superfunds, Barton and Barton, Universal Oil and Inglewood Lodge.

Phylogica fell 0.3 cents or 9.7 percent to 2.8 cents.